For diffuse large B cell lymphomas cells with EZH2 gain-of-function mutations that are resistant to EZH2 inhibitor treatment alone, combined inhibition of EZH2 and MEN1 effectively inhibited their proliferation (Chen et al., 2023). The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.